配戴接触镜引起角膜溃疡的护理

配戴接触镜引起角膜溃疡的护理刘波，李淑娟，郝凤荣（附属一院眼科）（附属二院眼科）黄红深，韩燕（市三院眼科）（中山区医院眼科）角膜接触镜是直接贴敷于眼球表面可以矫正屈光不正的眼镜，又称隐形或无形眼镜。随着社会进化和科技发展，全世界配戴隐形眼镜的人数日趋...     

氧氟沙星滴眼剂治疗细菌性角膜溃疡的疗效观察

氧氟沙星滴眼剂治疗细菌性角膜溃疡的疗效观察中山医科大学附属第三医院眼科（５１０６３０）戚朝秀，古财然，招泳婢，吴笑梅氧氟沙星（氟嗪酸，Ｏｆｌｏｘａｃｉｎ）作为一种新型抗生素被引进眼科领域，目前在国外眼科已普遍应用于治疗外眼感染性疾患［１］。１９９３年...     

酮康唑联合高压氧治疗真菌性角膜溃疡1例

酮康唑联合高压氧治疗真菌性角膜溃疡１例李前进，刘春和，尤毓陆（附院眼科，２６１０３１潍坊市人民医院高压氧科）患者，男，２５岁，工人。因突感右眼磨疼４ｄ于１９９３年７月３日来院诊治。无外伤史。体格检查无异常。眼科所见：右眼视力４．３，左眼５．２１眼压：...     

中西医结合治疗细菌性角膜溃疡

细菌性角膜溃疡是眼科常见病、多发病，如治疗不当或不及时治疗，可造成严重的视力障碍，甚至失明。据统计，在角膜疾病中，细菌性角膜溃疡致盲率最高（４２．２％）［１］。我科自１９９０年以来，用中西医结合治疗的方法治疗该病，取得了较好的疗效。现报告如下：１资料...     

咪康唑点眼治愈霉菌性角膜溃疡1例

<正> 患男,54岁。患糖尿病10年,1991年5月6日收内科住院治疗,用胰岛素等药物控制血糖后以双眼白内障于5月30日转入眼科。检查:右眼视力0.02,左眼视力眼前手动。双眼眼压2.74kPa。双眼晶体混浊,色觉和光定位正常,双眼ERG正常。     

手术治疗久治不愈角膜溃疡报告

<正>角膜病是眼科的一种多发病,也是致盲的主要眼病之一,由于抗菌药物及激素的广泛应用,基层缺乏抗病毒药物特别是抗真菌药物。临床上常遇到经久不愈的角膜溃疡,笔者通过手术治疗28例,取得较好疗效。报告如下,临床资料一、一般资料本组28例,男19例,女9例,其中右眼20例,左眼8例。溃疡直径3~8mm,病程1个月~3年,平均1年半。角膜刮片检出有菌丝6眼,全部病例术前均经大剂量抗菌药物及抗病毒药物治疗。     

角膜移植联合手术治疗感染性角膜溃疡穿孔8例报告

角膜移植联合手术治疗感染性角膜溃疡穿孔８例报告桂平市人民医院眼科黄立平陈明书郑树芬王卓妮感染性角膜溃疡穿孔是一种严重的眼病，可致盲或被迫摘除眼球。探讨一种有效的方法治疗感染性角膜溃疡穿孔，尽可能地保持有用视力，避免眼球摘除，具有十分重要的意义。我科１...     

角膜溃疡患者的病因分析及护理对策

角膜溃疡病是眼科致盲率较高的一种常见急症，其治疗效果与病因及诊治是否及时有关。现就我科2001～2003年就诊的67例角膜溃疡患者的临床资料进行病因分析，并提出相关护理对策。     

氟康唑联合那他霉素滴眼液治疗真菌性角膜溃疡

真菌性角膜溃疡已成为目前眼科临床较常见、治疗棘手、致盲率较高的眼部感染性疾患.大量广谱抗生素、皮质类固醇激素、免疫抑制剂的广泛应用,使得本病的发病率明显上升.由于眼科缺乏高效、低毒、广谱抗真菌的药物,真菌性角膜溃疡致盲率居高不下.我院近年来采用氟康唑联合那他霉素滴眼液治疗真菌性角膜溃疡, 取得了满意的效果.     

加味四妙勇安汤联合西药治疗真菌性角膜溃疡的临床研究

真菌性角膜溃疡是眼科的常见病、多发病,近年来随着抗生素和糖皮质激素在临床的广泛应用,有关真菌性角膜溃疡的文献报道日益增多,尤其是近十年来本病在我国发病率明显提高,已成为当前严重的感染性眼病之一。本病致盲率很高,治疗比较棘手,目前尚无特效疗法。近年来,笔者采用加味四妙勇安汤联合常规西药治疗本病20例,取得了满意疗效,现报道如下。1临床资料1.1一般资料36例(36眼)病例均为广州市中医医院眼科门诊及住院病人,随机分为治疗组和对照组。治疗组20例(20眼),其中男12例,女8例;年龄15岁～67岁,平均为43.6岁;病程最长者17d,最短者1d;其…     

Chinese herbal medicine Xinfeng Capsule in treatment of rheumatoid arthritis： study protocol of a multicenter randomized controlled trial

BACKGROUND： Rheumatoid arthritis （RA）, as a common systemic inflammatory autoimmune disease, affects approximately 1 in 100 individuals. Effective treatment for RA is not yet available because current research does not have a clear understanding of the etiology and pathogenesis of RA. Xinfeng Capsule, a patent Chinese herbal medicine, has been used in the treatment of RA in recent years. Despite its reported clinical efficacy, there are no large-sample, multicenter, randomized trials that support the use of Xinfeng Capsule for RA. Therefore, we designed a randomized, double-blind, multicenter, placebo-controlled trial to assess the efficacy and safety of Xinfeng Capsule in the treatment of RA. METHODS AND DESIGN： This is a 12-week, randomized, placebo-controlled, double-blind, multicenter trial on the treatment of RA. The participants will be randomly assigned to the experimental group and the control group at a ratio of 1：1. Participants in the experimental group will receive Xinfeng Capsule and a pharmaceutical placebo （imitation leflunomide）. The control group will receive leflunomide and an herbal placebo （imitation Xinfeng Capsule）. The American College of Rheumatology （ACR） Criteria for RA will be used to measure the efficacy of the Xinfeng Capsule. The primary outcome measure will be the percentage of study participants who achieve an ACR 20% response rate （ACR20）, which will be measured every 4 weeks after randomization. Secondary outcomes will include the ACR50 and ACR70 responses, the side effects of the medications, the Disease Activity Score 28, RA biomarkers, quality of life, and X-rays of the hands and wrists. The first four of the secondary outcomes will be measured every 4 weeks and the others will be measured at baseline and after 12 weeks of treatment. DISCUSSION： The result of this trial will help to evaluate whether Xinfeng Capsule is effective and safe in the treatment of RA. TRIAL REGISTRATION： This trial has been registered in ClinicalTrials.gov. The identifier is N CT01774877.     

Saffron （Crocus sativus L.） and major depressive disorder： a meta-analysis of randomized clinical trials

Due to safety concerns and side effects of many antidepressant medications, herbal psychopharmacology research has increased, and herbal remedies are becoming increasingly popular as alternatives to prescribed medications for the treatment of major depressive disorder （MDD）. Of these, accumulating trials reveal positive effects of the spice saffron （Crocus sativus L.） for the treatment of depression. A comprehensive and statistical review of the clinical trials examining the effects of saffron for treatment of MDD is warranted. OBJECTIVE： The purpose of this study was to conduct a meta-analysis of published randomized controlled trials examining the effects of saffron supplementation on symptoms of depression among participants with MDD. SEARCH STRATEGY： We conducted electronic and non-electronic searches to identify all relevant randomized, double-blind controlled trials. Reference lists of all retrieved articles were searched for relevant studies. INCLUSION CRITERIA： The criteria for study selection included the following： （1） adults （aged 18 and older） with symptoms of depression, （2） randomized controlled trial, （3） effects of saffron supplementation on depressive symptoms examined, and （4） study had either a placebo control or antidepressant comparison group. DATA EXTRACTION AND ANALYSIS： Using random effects modeling procedures, we calculated weighted mean effect sizes separately for the saffron supplementation vs placebo control groups, and for the saffron supplementation vs antidepressant groups. The methodological quality of all studies was assessed using the Jadad score. The computer software Comprehensive Meta- analysis 2 was used to analyze the data. RESULTS： Based on our pre-specified criteria, five randomized controlled trials （n = 2 placebo controlled trials, n = 3 antidepressant controlled trials） were included in our review. A large effect size was found for saffron supplementation vs placebo control in treating depressive symptoms （M ES = 1.62, P 〈 0.001）, revealing that saffron supplementation significantly reduced depression symptoms compared to the placebo control. A null effect size was evidenced between saffron supplementation and the antidepressant groups （M ES = -0.15） indicating that both treatments were similarly effective in reducing depression symptoms. The mean Jadad score was 5 indicating high quality of trials. CONCLUSION： Findings from clinical trials conducted to date indicate that saffron supplementation can improve symptoms of depression in adults with MDD. Larger clinical trials, conducted by research teams outside of Iran, with long-term follow-ups are needed before firm conclusions can be made regarding saffron＇s efficacy and safety for treating depressive symptoms.     

Association between intervertebral disc degeneration and disturbances of blood supply to the vertebrae

Low back pain is a common public health problem in western industrialized societies and the world as well.Studies indicate that the prevalence rate ranges to 35%, with around 10% of patients from 12% becoming chronically disabled. It also places an enormous economic burden on society. Although the exact cause of low back pain has yet to be defined, intervertebral disc degeneration is considered a major source of it. Since patients with degenerative discs are often asymptomatic, the mechanisms of it are still unclear.     

Relevance of muscle biopsy for diagnosing multifocal motor neuropathy

Multifocal motor neuropathy （MMN） is a rare,.focal,inflammatory,demyelinating disease of the peripheral nerves with pure motor involvementJ MMN is clinically characterized by slowly progressive,asymmetric,distal,upper limb predominant weakness,in the absence of sensory disturbances） Weakness is usually multifocal and connected to a distinct motor nerve,such as the musculocutaneous nerve resulting in biceps weakness,the posterior interosseus nerve resulting in finger drop,the median,ulnar,or radial nerve resulting in dexterity problems or grip weakness,or the peroneal nerve resulting in a foot drop.Onset of clinical manifestations is between 20 and 50 years of age.The prevalence of MMN is reported as 1-2 per 100 000.2 MMN is three times more frequent in men as compared to women.     

Modulating Effects of Chlorogenic Acid on Lipids and Glucose Metabolism and Expression of Hepatic Peroxisome Proliferator-activated Receptor-α in Golden Hamsters Fed on High Fat Diet

Objective To examine the effects of chlorogenic acid （CGA） on lipid and glucose metabolism under a high dietary fat burden and to explore the possible role of peroxisome proliferator-activated receptor-α （PPAR-α） in these effects. Methods Twenty male golden hamsters were randomly divided into CGA treatment group （n=10, given peritoneal injection of CGA solution prepared with PBS, 80 mg CGA/kg body weight daily）, and control group （n=10, given PBS i.p. at the average volume of the treatment group）. Animals in both groups were given 15% high fat diet. Eight weeks after treatment with CGA, the level of biochemical parameters in fasting serum and tissues and the expression of hepatic mRNA and protein PPAR-α were determined. Results Eight weeks after treatment with CGA, the levels of fasting serum triglyceride （TG）, free fatty acid （FFA）, total cholesterol （TC）, low density lipoprotein cholesterol （LDL-C）, high density lipoprotein cholesterol （HDL-C）, glucose （FSG）, and insulin （FSI） were significantly lower in the GGA treatment group than in the control group. CGA also led to higher activity of hepatic lipase （HL） lower contents of TG and FFA in liver, and lower activity of lipoprotein lipase （LPL） in skeletal muscle. Furthermore, CGA significantly elevated significantly elevated the expression level of mRNA and protein expression in hepatic PPAR-α. Conclusion CGA can modify lipids and glucose metabolism, which may be attributed to PPAR-α facilitated lipid clearance in liver and improved insulin sensitivity.     

痘苗病毒天坛株的减毒与其作为疫苗载体研究进展

1痘苗病毒天坛株的历史天花是人类历史上最可怕的传染病之一。天花由天花病毒（variola virus）引起,人是该病毒的惟一宿主。人感染天花病毒后的死亡率达到30%~40%[1]。世界上公认的对天花最早的准确记录来自中国,晋代药学家葛洪于公元430年左右,在《肘后备急方》中对天花有清楚的描述[1]。     

The role of central nervous system on hypoglycemia and the feasibility of the brain theory in traditional Chinese medicine on treatment of diabetes mellitus

The central nervous system （CNS） plays a key regulatory role in glucose homeostasis. In particular, the brain is important in initiating and coordinating protective counterregulatory responses when blood glucose levels fall. This may due to the metabolic dependency of the CNS on glucose, and protection of food supply to the brain. In healthy subjects, blood glucose is normally maintained within a relatively narrow range. Hypoglycemia in diabetic patients can increase the risk of complications, such as heart disease and diabetic peripheral neuropathy. The clinical research finds that the use of traditional Chinese medicine （TCM） has a positive effect on the treatment of hypoglycemia. Here the authors reviewed the current understanding of sensing and counterregulatory responses to hypoglycemia, and discuss combining traditional Chinese and Western medicine and the theory of iatrogenic hypoglycemia in diabetes treatment. Furthermore, the authors clarify the feasibility of treating hypoglycemia on the basis of TCM theory and CNS and have an insight on its clinical practice.